{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T20:36:51Z","timestamp":1764794211167,"version":"3.37.3"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2021,3,8]],"date-time":"2021-03-08T00:00:00Z","timestamp":1615161600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,3,8]],"date-time":"2021-03-08T00:00:00Z","timestamp":1615161600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Perinatol"],"published-print":{"date-parts":[[2021,6]]},"DOI":"10.1038\/s41372-021-01021-w","type":"journal-article","created":{"date-parts":[[2021,3,8]],"date-time":"2021-03-08T14:03:43Z","timestamp":1615212223000},"page":"1426-1431","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Hypertension in neonates treated with intravitreal bevacizumab for retinopathy of prematurity"],"prefix":"10.1038","volume":"41","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8816-7969","authenticated-orcid":false,"given":"Grace","family":"Twitty","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Weiss","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Catalina","family":"Bazacliu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keliana","family":"O\u2019Mara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meredith E.","family":"Mowitz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,3,8]]},"reference":[{"key":"1021_CR1","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1542\/neo.13-8-e476","volume":"13","author":"RA Silva","year":"2012","unstructured":"Silva RA, Moshfeghi DM. Interventions in retinopathy of prematurity. NeoReviews. 2012;13:476.","journal-title":"NeoReviews."},{"key":"1021_CR2","doi-asserted-by":"publisher","first-page":"2208","DOI":"10.1097\/IAE.0000000000001719","volume":"37","author":"Y Yonekawa","year":"2017","unstructured":"Yonekawa Y, Thomas BJ, Thanos A, Todorich B, Drenser KA, Trese MT, et al. The cutting edge of retinopathy of prematurity care: expanding the boundaries of diagnosis and treatment. Retina. 2017;37:2208\u201325.","journal-title":"Retina."},{"key":"1021_CR3","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1016\/j.clp.2014.08.011","volume":"41","author":"ME Hartnett","year":"2014","unstructured":"Hartnett ME. Vascular endothelial growth factor antagonist therapy for retinopathy of prematurity. Clin Perinatol. 2014;41:925\u201343.","journal-title":"Clin Perinatol"},{"key":"1021_CR4","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1542\/peds.2018-3537","volume":"144","author":"G Natarajan","year":"2019","unstructured":"Natarajan G, Shankaran S, Nolen TL, Sridhar A, Kennedy KA, Hintz SR, et al. Neurodevelopmental outcomes of preterm infants with retinopathy of prematurity by treatment. Pediatrics. 2019;144:2.","journal-title":"Pediatrics."},{"key":"1021_CR5","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/j.pharmthera.2017.08.012","volume":"182","author":"M Li","year":"2018","unstructured":"Li M, Kroetz DL. Bevacizumab-induced hypertension: clinical presentation and molecular understanding. Pharm Ther. 2018;182:152\u201360.","journal-title":"Pharm Ther"},{"key":"1021_CR6","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1542\/peds.2015-3218","volume":"137","author":"J Morin","year":"2016","unstructured":"Morin J, Luu TM, Superstein R, Ospina LH, Lefebvre F, Simard MN, et al. Neurodevelopmental outcomes following bevacizumab injections for retinopathy of prematurity. Pediatrics. 2016;137:4\u20136.","journal-title":"Pediatrics."},{"key":"1021_CR7","doi-asserted-by":"publisher","first-page":"xxiii","DOI":"10.1016\/j.ajo.2017.10.027","volume":"186","author":"P Sternberg","year":"2018","unstructured":"Sternberg P, Durrani AK. Evolving concepts in the management of retinopathy of prematurity. Am J Ophthalmol. 2018;186:xxiii\u2013xxxii.","journal-title":"Am J Ophthalmol"},{"key":"1021_CR8","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1056\/NEJMoa1007374","volume":"364","author":"HA Mintz-Hittner","year":"2011","unstructured":"Mintz-Hittner HA, Kennedy KA, Chuang AZ, Group, RC B-. Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity. N. Engl J Med. 2011;364:603\u201315.","journal-title":"N. Engl J Med"},{"key":"1021_CR9","doi-asserted-by":"publisher","first-page":"126","DOI":"10.3928\/23258160-20180129-07","volume":"49","author":"TA Chen","year":"2018","unstructured":"Chen TA, Schachar IH, Moshfeghi DM. Outcomes of intravitreal bevacizumab and diode laser photocoagulation for treatment-warranted retinopathy of prematurity. Ophthalmic Surg Lasers Imaging Retin. 2018;49:126\u201331.","journal-title":"Ophthalmic Surg Lasers Imaging Retin"},{"key":"1021_CR10","doi-asserted-by":"publisher","first-page":"1300","DOI":"10.1038\/s41372-019-0420-z","volume":"39","author":"K Raghuram","year":"2019","unstructured":"Raghuram K, Isaac M, Yang J, AlAli A, Mireskandari K, Ly LG, et al. Neurodevelopmental outcomes in infants treated with intravitreal bevacizumab versus laser. J Perinatol. 2019;39:1300\u20138.","journal-title":"J Perinatol"},{"key":"1021_CR11","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1016\/j.ygyno.2017.09.017","volume":"147","author":"MK Frey","year":"2017","unstructured":"Frey MK, Dao F, Olvera N, Konner JA, Dickler MN, Levine DA. Genetic predisposition to bevacizumab-induced hypertension. Gynecol Oncol. 2017;147:621\u20135.","journal-title":"Gynecol Oncol"},{"key":"1021_CR12","doi-asserted-by":"publisher","first-page":"159","DOI":"10.2165\/11590180-000000000-00000","volume":"25","author":"KN Syrigos","year":"2011","unstructured":"Syrigos KN, Karapanagiotou E, Boura P, Manegold C, Harrington K. Bevacizumab-induced hypertension: pathogenesis and management. BioDrugs. 2011;25:159\u201369.","journal-title":"BioDrugs."},{"key":"1021_CR13","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1007\/s10637-010-9549-5","volume":"30","author":"O Mir","year":"2012","unstructured":"Mir O, Coriat R, Ropert S, Cabanes L, Blanchet B, Camps S, et al. Treatment of bevacizumab-induced hypertension by amlodipine. Investig N. Drugs. 2012;30:702\u20137.","journal-title":"Investig N. Drugs"},{"key":"1021_CR14","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1002\/cncr.28972","volume":"121","author":"OP Hamnvik","year":"2015","unstructured":"Hamnvik OP, Choueiri TK, Turchin A, McKay RR, Goyal L, Davis M, et al. Clinical risk factors for the development of hypertension in patients treated with inhibitors of the VEGF signaling pathway. Cancer. 2015;121:311\u20139.","journal-title":"Cancer."},{"key":"1021_CR15","doi-asserted-by":"publisher","first-page":"1714","DOI":"10.1038\/eye.2008.360","volume":"23","author":"R Rasier","year":"2009","unstructured":"Rasier R, Artunay O, Yuzbasioglu E, Sengul A, Bahcecioglu H. The effect of intravitreal bevacizumab (avastin) administration on systemic hypertension. Eye. 2009;23:1714\u20138.","journal-title":"Eye"},{"key":"1021_CR16","doi-asserted-by":"publisher","first-page":"1636","DOI":"10.1136\/bjophthalmol-2014-305252","volume":"98","author":"RL Avery","year":"2014","unstructured":"Avery RL, Castellarin AA, Steinle NC, Dhoot DS, Pieramici DJ, See R, et al. Systemic pharmacokinetics following intravitreal injections of ranibizumab, bevacizumab or aflibercept in patients with neovascular AMD. Br J Ophthalmol. 2014;98:1636\u201341.","journal-title":"Br J Ophthalmol"},{"key":"1021_CR17","doi-asserted-by":"crossref","first-page":"2050313X2090703","DOI":"10.1177\/2050313X20907033","volume":"8","author":"RM Hanna","year":"2020","unstructured":"Hanna RM, Abdelnour L, Hasnain H, Selamet U, Kurtz I. Intravitreal bevacizumab-induced exacerbation of proteinuria in diabetic nephropathy, and amelioration by switching to ranibizumab. SAGE Open Med Case Rep. 2020;8:2050313X20907033.","journal-title":"SAGE Open Med Case Rep"},{"key":"1021_CR18","doi-asserted-by":"publisher","first-page":"e357","DOI":"10.1542\/neo.18-6-e357","volume":"18","author":"K Mistry","year":"2017","unstructured":"Mistry K, Gupta C. Neonatal hypertension. Neoreviews. 2017;18:e357\u2013e371.","journal-title":"Neoreviews."},{"key":"1021_CR19","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.jpeds.2012.12.074","volume":"163","author":"R Sahu","year":"2013","unstructured":"Sahu R, Pannu H, Yu R, Shete S, Bricker JT, Gupta-Malhotra M. Systemic hypertension requiring treatment in the neonatal intensive care unit. J Pediatr. 2013;163:84\u201388.","journal-title":"J Pediatr"},{"key":"1021_CR20","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1542\/pir.2019-0159","volume":"41","author":"P Giri","year":"2020","unstructured":"Giri P, Roth P. Neonatal hypertension. Pediatr Rev. 2020;41:307\u201311.","journal-title":"Pediatr Rev"},{"key":"1021_CR21","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1016\/j.cjca.2014.02.011","volume":"30","author":"HY Small","year":"2014","unstructured":"Small HY, Montezano AC, Rios FJ, Savoia C, Touyz RM. Hypertension due to antiangiogenic cancer therapy with vascular endothelial growth factor inhibitors: understanding and managing a new syndrome. Can J Cardiol. 2014;30:534\u201343.","journal-title":"Can J Cardiol"},{"key":"1021_CR22","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1080\/20009666.2018.1478563","volume":"8","author":"M Hamid","year":"2018","unstructured":"Hamid M, Ghani A, Micaily I, Sarwar U, Lashari B, Malik F. Posterior reversible encephalopathy syndrome (PRES) after bevacizumab therapy for metastatic colorectal cancer. J Community Hosp Intern Med Perspect. 2018;8:130\u20133.","journal-title":"J Community Hosp Intern Med Perspect"},{"key":"1021_CR23","doi-asserted-by":"publisher","first-page":"1961","DOI":"10.1016\/j.ophtha.2018.05.001","volume":"125","author":"DK Wallace","year":"2018","unstructured":"Wallace DK, Dean TW, Hartnett ME, Kong L, Smith LE, Hubbard GB, et al. A dosing study of bevacizumab for retinopathy of prematurity: late recurrences and additional treatments. Ophthalmology. 2018;125:1961\u20136.","journal-title":"Ophthalmology."},{"key":"1021_CR24","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1136\/bjo.2008.141481","volume":"92","author":"JE Sears","year":"2008","unstructured":"Sears JE. Anti-vascular endothelial growth factor and retinopathy of prematurity. Br J Ophthalmol. 2008;92:1437\u20138.","journal-title":"Br J Ophthalmol"},{"key":"1021_CR25","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1167\/iovs.14-15842","volume":"56","author":"L Kong","year":"2015","unstructured":"Kong L, Bhatt AR, Demny AB, Coats DK, Li A, Rahman EZ, et al. Pharmacokinetics of bevacizumab and its effects on serum VEGF and IGF-1 in infants with retinopathy of prematurity. Invest Ophthalmol Vis Sci. 2015;56:956\u201361.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"1021_CR26","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1634\/theoncologist.2014-0149","volume":"20","author":"S Singer","year":"2015","unstructured":"Singer S, Grommes C, Reiner AS, Rosenblum MK, DeAngelis LM. Posterior reversible encephalopathy syndrome in patients with cancer. Oncologist. 2015;20:806\u201311.","journal-title":"Oncologist."},{"key":"1021_CR27","first-page":"1","volume":"2013","author":"O Abbas","year":"2013","unstructured":"Abbas O, Shamseddin A, Temraz S, Haydar A. Posterior reversible encephalopathy syndrome after bevacizumab therapy in a normotensive patient. BMJ Case Rep. 2013;2013:1.","journal-title":"BMJ Case Rep."},{"key":"1021_CR28","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.jocn.2017.01.005","volume":"40","author":"J Massey","year":"2017","unstructured":"Massey J. Posterior reversible encephalopathy syndrome (PRES) with sub-arachnoid haemorrhage after bevacizumab and 5-FU. J Clin Neurosci. 2017;40:57\u201359.","journal-title":"J Clin Neurosci"},{"key":"1021_CR29","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1093\/qjmed\/hcr139","volume":"105","author":"RC Seet","year":"2012","unstructured":"Seet RC, Rabinstein AA. Clinical features and outcomes of posterior reversible encephalopathy syndrome following bevacizumab treatment. QJM. 2012;105:69\u201375.","journal-title":"QJM."},{"key":"1021_CR30","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1089\/jop.2009.0148","volume":"26","author":"O Artunay","year":"2010","unstructured":"Artunay O, Yuzbasioglu E, Rasier R, Sengul A, Bahcecioglu H. Posterior reversible encephalopathy syndrome after intravitreal bevacizumab injection in patient with choroidal neovascular membrane secondary to age-related maculopathy. J Ocul Pharm Ther. 2010;26:301\u20133.","journal-title":"J Ocul Pharm Ther"},{"key":"1021_CR31","first-page":"1","volume":"4","author":"G Twitty","year":"2019","unstructured":"Twitty G, Weiss M, Albayram MS, O\u2019Mara K, Mowitz ME. Hypertension and neuroimaging changes after bevacizumab for retinopathy of prematurity. Pediatrics. 2019;4:1\u20132.","journal-title":"Pediatrics."},{"doi-asserted-by":"crossref","unstructured":"Zayek M, Parker K, Rydzewska M, Rifai A, Bhat R, Eyal F. Bevacizumab for retinopathy of prematurity: 2-year neurodevelopmental follow-up. Am J Perinatol. 2020:1.","key":"1021_CR32","DOI":"10.1055\/s-0040-1710556"},{"key":"1021_CR33","doi-asserted-by":"publisher","first-page":"e20152005","DOI":"10.1542\/peds.2015-2005","volume":"137","author":"LH Wu","year":"2016","unstructured":"Wu LH, Yang YH, Lin CH, Lin YJ, Cheng CL. Hypotension associated with intravitreal bevacizumab therapy for retinopathy of prematurity. Pediatrics 2016;137:e20152005.","journal-title":"Pediatrics"}],"container-title":["Journal of Perinatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41372-021-01021-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41372-021-01021-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41372-021-01021-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T21:32:13Z","timestamp":1684618333000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41372-021-01021-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,8]]},"references-count":33,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021,6]]}},"alternative-id":["1021"],"URL":"https:\/\/doi.org\/10.1038\/s41372-021-01021-w","relation":{},"ISSN":["0743-8346","1476-5543"],"issn-type":[{"type":"print","value":"0743-8346"},{"type":"electronic","value":"1476-5543"}],"subject":[],"published":{"date-parts":[[2021,3,8]]},"assertion":[{"value":"30 November 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 January 2021","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 February 2021","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 March 2021","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}